Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Launched by EARLY IS GOOD INC. · Aug 6, 2023

Keywords

ClinConnect Summary

This clinical trial is testing a new urine test called BCDx, which helps doctors find out if bladder cancer has come back in patients who have already been diagnosed with a specific type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The goal is to see how well this test works compared to the usual check-ups that involve looking inside the bladder with a camera (a procedure called cystoscopy). This study is non-invasive, meaning it doesn't require any surgery or painful procedures, making it easier for patients.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with NMIBC within the last two years. You should also be undergoing regular monitoring for your bladder cancer. If you're planning to have surgery to remove your bladder or receive chemotherapy or radiation treatment for bladder cancer, you won't be eligible for this study. Participants will provide a urine sample, and by joining, you'll help researchers learn more about this new test, potentially improving how bladder cancer is monitored in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 Years and older
• • Patients who have been diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing standard of care/routine monitoring cystoscopy.
• • Patients who are able to provide legally effective informed consent.
• • Patients who are able to provide minimum 30mL of voided urine.
• Exclusion Criteria:
• • Patients planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma.